Toshiba may forgo the highest bid for its semiconductor business, from Hon Hai Precision Industry, because of likely opposition from the Japanese and American governments, according to people familiar with the matter.
Taiwan’s Hon Hai, which has indicated its willingness to pay as much as $27 billion for the chip unit, would face resistance because of its ties to China, said the sources who asked to not be identified because the matter is private. That could drag out regulatory approvals and delay badly needed cash payments to Toshiba, raising the risks of such a deal, the people said. Hon Hai, the primary iPhone assembler for Apple, has most of its factories in mainland China.
As a result, Toshiba is giving serious consideration to lower bids, including a potential offer of about $18 billion from US chip-maker Broadcom, the people said. The Japanese government is organizing an alternative offer from Japanese companies that aims to inject $4.5 billion into the chip unit in exchange for a minority stake, one person said. Current bids are nonbinding and could change. The deadline for the next round of bidding is mid-May, one of the people said.
Full Content: Japan Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas